Study on Evexomostat with PI3K or AKT Inhibitor and Fulvestrant for Women with PI3K Alteration and HR+/HER2- Breast Cancer | Clinical Trial

Study on Evexomostat with PI3K or AKT Inhibitor and Fulvestrant for Women with PI3K Alteration and HR+/HER2- Breast Cancer | Clinical Trial | Right2Hope